+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Viral Vector and Plasmid DNA Manufacturing Market: Global Industry Analysis, Trends, Market Size, and Forecasts up to 2025

  • ID: 4840939
  • Report
  • August 2019
  • Region: Global
  • 100 pages
  • Infinium Global Research
1 of 3

FEATURED COMPANIES

  • CobraBiologics
  • Kaneka Eurogentec S.A.
  • Lonza
  • Merck KGaA
  • Novasep Inc.
  • Spark Therapeutics, Inc.
  • MORE
The report on the global viral vector and plasmid DNA manufacturing market provides qualitative and quantitative analysis for the period from 2017 to 2025. The report predicts the global viral vector and plasmid DNA manufacturing market to grow with a CAGR of 16.2% over the forecast period from 2019-2025. The study on viral vector and plasmid DNA manufacturing market covers the analysis of the leading geographies such as North America, Europe, Asia-Pacific, and RoW for the period of 2017 to 2025.

The report on viral vector and plasmid DNA manufacturing market is a comprehensive study and presentation of drivers, restraints, opportunities, demand factors, market size, forecasts, and trends in the global viral vector and plasmid DNA manufacturing market over the period of 2017 to 2025. Moreover, the report is a collective presentation of primary and secondary research findings.

Porter's five forces model in the report provides insights into the competitive rivalry, supplier and buyer positions in the market and opportunities for the new entrants in the global viral vector and plasmid DNA manufacturing market over the period of 2017 to 2025. Further, Growth Matrix gave in the report brings an insight into the investment areas that existing or new market players can consider.

Report Findings

1) Drivers
  • The rise in incidence rates of cancer is one of the major drivers
  • Genetic disorders and infectious diseases also fuel the growth of the market
  • High unmet needs in patients with rare disorders and raised acceptance for comparatively newer treatment options in developing countries
2) Restraints
  • The high cost of gene therapies may restrain the growth of the market
3) Opportunities
  • The untapped potential of emerging countries
Research Methodology

A) Primary Research
Our primary research involves extensive interviews and analysis of the opinions provided by the primary respondents. The primary research starts with identifying and approaching the primary respondents, the primary respondents are approached include
1. Key Opinion Leaders associated with Author
2. Internal and External subject matter experts
3. Professionals and participants from the industry

Our primary research respondents typically include
1. Executives working with leading companies in the market under review
2. Product/brand/marketing managers
3. CXO level executives
4. Regional/zonal/ country managers
5. Vice President level executives.

B) Secondary Research
Secondary research involves extensive exploring through the secondary sources of information available in both the public domain and paid sources. Each research study is based on over 500 hours of secondary research accompanied by primary research. The information obtained through the secondary sources is validated through the crosscheck on various data sources.

The secondary sources of the data typically include
1. Company reports and publications
2. Government/institutional publications
3. Trade and associations journals
4. Databases such as WTO, OECD, World Bank, and among others.
5. Websites and publications by research agencies

Segment Covered
The global viral vector and plasmid DNA manufacturing market is segmented on the basis of type, application, disease, and end-user.

The Global Viral Vector and Plasmid DNA Manufacturing Market by Type
  • Adenovirus
  • Lentivirus
  • Adeno-associated Virus
  • Plasmid DNA
  • Other Type
The Global Viral Vector and Plasmid DNA Manufacturing Market by Application
  • Gene Therapy
  • Vaccinology
  • Other Applications
The Global Viral Vector and Plasmid DNA Manufacturing Market by Disease
  • Cancer
  • Genetic Disorders
  • Infectious Disease
  • Other Disease
The Global Viral Vector and Plasmid DNA Manufacturing Market by End-User
  • Biotech Companies
  • Research Institutes
Company Profiles
The companies covered in the report include
  • CobraBiologics
  • Novasep Inc.
  • Cell and Gene Therapy Catapult
  • Kaneka Eurogentec S.A.
  • FUJIFILM Diosynth Biotechnologies Inc.
  • Spark Therapeutics, Inc.
  • Merck KGaA
  • uniQure N.V.
  • Lonza
What does this report deliver?
1. Comprehensive analysis of the global as well as regional markets of the viral vector and plasmid DNA manufacturing market.
2. Complete coverage of all the segments in the viral vector and plasmid DNA manufacturing market to analyze the trends, developments in the global market and forecast of market size up to 2025.
3. Comprehensive analysis of the companies operating in the global viral vector and plasmid DNA manufacturing market. The company profile includes analysis of product portfolio, revenue, SWOT analysis and latest developments of the company.
4. Growth Matrix presents an analysis of the product segments and geographies that market players should focus to invest, consolidate, expand and/or diversify.
Note: Product cover images may vary from those shown
2 of 3

FEATURED COMPANIES

  • CobraBiologics
  • Kaneka Eurogentec S.A.
  • Lonza
  • Merck KGaA
  • Novasep Inc.
  • Spark Therapeutics, Inc.
  • MORE
1. Preface
1.1. Report Description
1.2. Research Methods
1.3. Research Approaches

2. Executive Summary
2.1. Viral Vector and Plasmid DNA Manufacturing Market Highlights
2.2. Viral Vector and Plasmid DNA Manufacturing Market Projection
2.3. Viral Vector and Plasmid DNA Manufacturing Market Regional Highlights

3. Global Viral Vector and Plasmid DNA Manufacturing Market Overview
3.1. Introduction
3.2. Market Dynamics
3.2.1. Drivers
3.2.2. Restraints
3.2.3. Opportunities
3.3. Porter's Five Forces Analysis
3.4. Growth Matrix Analysis
3.4.1. Growth Matrix Analysis by Type
3.4.2. Growth Matrix Analysis by Application
3.4.3. Growth Matrix Analysis by Disease
3.4.4. Growth Matrix Analysis by End-user
3.4.5. Growth Matrix Analysis by Region
3.5. Value Chain Analysis of Viral Vector and Plasmid DNA Manufacturing Market

4. Viral Vector and Plasmid DNA Manufacturing Market Macro Indicator Analysis

5. Global Viral Vector and Plasmid DNA Manufacturing Market by Type
5.1. Adenovirus
5.2. Lentivirus
5.3. Adeno-associated Virus
5.4. Plasmid DNA
5.5. Other Type

6. Global Viral Vector and Plasmid DNA Manufacturing Market by Application
6.1. Gene Therapy
6.2. Vaccinology
6.3. Other Applications

7. Global Viral Vector and Plasmid DNA Manufacturing Market by Disease
7.1. Cancer
7.2. Genetic Disorders
7.3. Infectious Disease
7.4. Other Disease

8. Global Viral Vector and Plasmid DNA Manufacturing Market by End-user
8.1. Biotech Companies
8.2. Research Institutes

9. Global Viral Vector and Plasmid DNA Manufacturing Market by Region 2019-2025
9.1. North America
9.1.1. North America Viral Vector and Plasmid DNA Manufacturing Market by Type
9.1.2. North America Viral Vector and Plasmid DNA Manufacturing Market by Application
9.1.3. North America Viral Vector and Plasmid DNA Manufacturing Market by Disease
9.1.4. North America Viral Vector and Plasmid DNA Manufacturing Market by End-user
9.1.5. North America Viral Vector and Plasmid DNA Manufacturing Market by Country
9.2. Europe
9.2.1. Europe Viral Vector and Plasmid DNA Manufacturing Market by Type
9.2.2. Europe Viral Vector and Plasmid DNA Manufacturing Market by Application
9.2.3. Europe Viral Vector and Plasmid DNA Manufacturing Market by Disease
9.2.4. Europe Viral Vector and Plasmid DNA Manufacturing Market by End-user
9.2.5. Europe Viral Vector and Plasmid DNA Manufacturing Market by Country
9.3. Asia-Pacific
9.3.1. Asia-Pacific Viral Vector and Plasmid DNA Manufacturing Market by Type
9.3.2. Asia-Pacific Viral Vector and Plasmid DNA Manufacturing Market by Application
9.3.3. Asia-Pacific Viral Vector and Plasmid DNA Manufacturing Market by Disease
9.3.4. Asia-Pacific Viral Vector and Plasmid DNA Manufacturing Market by End-user
9.3.5. Asia-Pacific Viral Vector and Plasmid DNA Manufacturing Market by Country
9.4. RoW
9.4.1. RoW Viral Vector and Plasmid DNA Manufacturing Market by Type
9.4.2. RoW Viral Vector and Plasmid DNA Manufacturing Market by Application
9.4.3. RoW Viral Vector and Plasmid DNA Manufacturing Market by Disease
9.4.4. RoW Viral Vector and Plasmid DNA Manufacturing Market by End-user
9.4.5. RoW Viral Vector and Plasmid DNA Manufacturing Market by Sub-region

10. Company Profiles and Competitive Landscape
10.1. Competitive Landscape in the Global Viral Vector and Plasmid DNA Manufacturing Market
10.2. Companies Profiles
10.2.1. CobraBiologics
10.2.2. Novasep Inc.
10.2.3. Cell and Gene Therapy Catapult
10.2.4. Kaneka Eurogentec S.A.
10.2.5. FUJIFILM Diosynth Biotechnologies Inc.
10.2.6. Spark Therapeutics, Inc.
10.2.7. Merck KGaA
10.2.8. uniQure N.V.
10.2.9. Lonza

11. Appendix
11.1. Primary Research Findings and Questionnaire
Note: Product cover images may vary from those shown
3 of 3
  • CobraBiologics
  • Novasep Inc.
  • Cell and Gene Therapy Catapult
  • Kaneka Eurogentec S.A.
  • FUJIFILM Diosynth Biotechnologies Inc.
  • Spark Therapeutics, Inc.
  • Merck KGaA
  • uniQure N.V.
  • Lonza
Note: Product cover images may vary from those shown
Adroll
adroll